Key result
Whole-genome sequencing identifies no significant variants in canine MMVD after multiple-testing correction.
Why the study?
Myxomatous mitral valve disease is the most prevalent acquired cardiac disease in dogs and serves as a model for human mitral valve prolapse, yet its molecular and genetic underpinnings remain poorly understood.
Case-Control (n=10)
Answers are grounded in this paper and cite their sources.
This pilot canine whole-genome sequencing study highlights extracellular matrix collagen genes (COL12A1 and COL1A2) as uncertain candidate loci for myxomatous mitral valve disease, requiring validation in larger cohorts.
Myxomatous mitral valve disease (MMVD) is the most prevalent acquired cardiac disease in dogs and represents an important comparative model for human mitral valve prolapse (MVP). Although the structural pathology of MMVD is well described, its molecular and genetic underpinnings remain poorly understood. In this pilot study, we performed whole-genome sequencing (WGS) at approximately 30× coverage on eight MMVD-affected and two unaffected Maltese dogs. Variants were called following the GATK best-practices pipeline, and allele frequencies were compared between cases and controls with Fisher’s exact test across 67 canine MMVD candidate genes and 65 canine orthologs of human MVP genes. Multiple testing was assessed by false discovery rate and Bonferroni correction, and gene- and gene-set-level significance by permutation of case–control labels. No variant remained significant after correction; with 16 case and 4 control alleles, the smallest attainable p-value was 2.1 × 10−4. In the canine set, 17 genes had nominal p < 0.05, more than expected under permutation (empirical p = 0.044); the lowest p-values were in COL12A1 (p = 0.0031; empirical p = 0.022) and COL1A2 (p = 0.0035; empirical p = 0.044), both encoding collagens of the extracellular matrix (ECM). Several canine signals (CDK6, HEPACAM2 and VPS50) lay in a single haplotype block on chromosome 14, 1.2 Mb from COL1A2. The human MVP-orthologous set showed no excess of nominal genes (empirical p = 0.756). No close relatives or major population structure were detected. These pilot results point to collagen and ECM-related loci as uncertain candidates; larger studies with balanced, sex-matched case and control groups and older, echocardiographically confirmed controls are needed before these candidates are tested.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) conducted a case-control in Myxomatous mitral valve disease (MMVD) (n=10). Whole-genome sequencing (WGS) of MMVD candidate genes and human MVP orthologs vs. Unaffected Maltese dogs (n=2) was evaluated on Allele frequency differences across 67 canine MMVD candidate genes and 65 canine orthologs of human MVP genes (p=0.044 (empirical p for canine candidate gene set)). Whole-genome sequencing in Maltese dogs with MMVD identified no significant variants after correction, though 17 canine candidate genes showed nominal.
Synapse has enriched 10 related papers. Consider them for comparative context: